Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug954 | Cyclosporine Wiki | 0.37 |
drug944 | Crisis management coaching Wiki | 0.28 |
drug3431 | Text message Wiki | 0.28 |
Name (Synonyms) | Correlation | |
---|---|---|
drug1643 | In-Person Default Wiki | 0.28 |
drug1243 | Exercise training group Wiki | 0.28 |
drug2732 | Quantitative IgG Test Wiki | 0.28 |
drug3392 | Telehealth coaching sessions Wiki | 0.28 |
drug819 | Coala Heart Monitor Wiki | 0.28 |
drug1966 | Maraviroc + Currently used therapy Wiki | 0.28 |
drug932 | Covax-19™ Wiki | 0.28 |
drug939 | Covid-19 swab PCR test Wiki | 0.28 |
drug1794 | LIIT.CI ACT Wiki | 0.28 |
drug3941 | life questionnaires Wiki | 0.28 |
drug1837 | Lifestyle intervention Wiki | 0.28 |
drug1712 | Intervention-EDI and health coaching Wiki | 0.28 |
drug892 | Control-EDI Wiki | 0.28 |
drug1301 | Favipiravir + Currently used therapy Wiki | 0.28 |
drug936 | Covid-19 Rapid Test Kit (RAPG-COV-019) Wiki | 0.28 |
drug950 | Curently used therapy for COVID-19 non-critical patients Wiki | 0.28 |
drug940 | Covid19 Wiki | 0.28 |
drug955 | CytoSorb Wiki | 0.28 |
drug934 | Covid-19 + patients Wiki | 0.28 |
drug1190 | Enhanced Chronic Disease Self-management program Wiki | 0.28 |
drug1125 | EHR-based Clinician Jumpstart Wiki | 0.28 |
drug952 | Customized questionnaire Wiki | 0.28 |
drug3646 | Video Default Wiki | 0.28 |
drug1968 | Maraviroc+Favipiravir+CT Wiki | 0.28 |
drug168 | Active Choice Wiki | 0.28 |
drug1795 | LIIT.CI CFT Wiki | 0.28 |
drug3321 | SyB V-1901 Wiki | 0.28 |
drug4069 | questionnaire Wiki | 0.14 |
drug895 | Convalescent Plasma Wiki | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
D000071069 | Multiple Chronic Conditions NIH | 0.28 |
D006337 | Heart Murmurs NIH | 0.28 |
D051436 | Renal Insufficiency, Chronic NIH | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
D016491 | Peripheral Vascular Diseases NIH | 0.20 |
D000073296 | Noncommunicable Diseases NIH | 0.20 |
D007674 | Kidney Diseases NIH | 0.17 |
D058729 | Peripheral Arterial Disease NIH | 0.16 |
D008269 | Macular Edema NIH | 0.16 |
D011111 | Polymyalgia Rheumatica NIH | 0.16 |
D013700 | Giant Cell Arteritis NIH | 0.16 |
D014652 | Vascular Diseases NIH | 0.14 |
D009362 | Neoplasm Metastasis NIH | 0.14 |
D008103 | Liver Cirrhosis, NIH | 0.14 |
D051437 | Renal Insufficiency, NIH | 0.12 |
D006973 | Hypertension NIH | 0.12 |
D007154 | Immune System Diseases NIH | 0.11 |
D063766 | Pediatric Obesity NIH | 0.11 |
D000066553 | Problem Behavior NIH | 0.10 |
D050177 | Overweight NIH | 0.10 |
D007676 | Kidney Failure, Chronic NIH | 0.10 |
D006333 | Heart Failure NIH | 0.09 |
D008175 | Lung Neoplasms NIH | 0.09 |
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.08 |
D017563 | Lung Diseases, Interstitial NIH | 0.08 |
D009103 | Multiple Sclerosis NIH | 0.08 |
D008171 | Lung Diseases, NIH | 0.06 |
D001523 | Mental Disorders NIH | 0.05 |
D002318 | Cardiovascular Diseases NIH | 0.05 |
D007249 | Inflammation NIH | 0.05 |
D009369 | Neoplasms, NIH | 0.05 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0030148 | Heart murmur HPO | 0.28 |
HP:0012622 | Chronic kidney disease HPO | 0.23 |
HP:0011505 | Cystoid macular edema HPO | 0.20 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000077 | Abnormality of the kidney HPO | 0.18 |
HP:0000822 | Hypertension HPO | 0.14 |
HP:0001395 | Hepatic fibrosis HPO | 0.14 |
HP:0004950 | Peripheral arterial stenosis HPO | 0.12 |
HP:0000083 | Renal insufficiency HPO | 0.12 |
HP:0000708 | Behavioral abnormality HPO | 0.10 |
HP:0100526 | Neoplasm of the lung HPO | 0.10 |
HP:0001635 | Congestive heart failure HPO | 0.09 |
HP:0006510 | Chronic pulmonary obstruction HPO | 0.09 |
HP:0006515 | Interstitial pneumonitis HPO | 0.08 |
HP:0002088 | Abnormal lung morphology HPO | 0.06 |
HP:0002664 | Neoplasm HPO | 0.05 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.05 |
Navigate: Correlations HPO
There are 13 clinical trials
Children and adolescents with overweight and obesity are predisposed to significant health problems. It is known that childhood obesity can adversely affect almost every organ system, and if left untreated, the major impact of childhood overweight is likely to be felt in the next generation of adults. The aim of " Kijk op overgewicht bij kinderen" is to collect and follow-up longitudinal data from a population of different degrees of children with overweight regarding etiological factors, risk factors and early stages of chronic disease in different degrees of childhood overweight.
In this trial, the investigators will examine whether text messages sent to Veterans will help support in meeting nutrition or physical activity health goals. All participants will get text messages over two month to support their goal.
Description: Self-reported confidence in performing healthful diet and physical activity behaviors. Self-efficacy - Healthful eating via Revised Eating Self-Efficacy Scale (ESES-R). Range: 1-10; higher values represent a better outcome.
Measure: Self-efficacy: Healthful eating via Revised Eating Self-Efficacy Scale (ESES-R) Time: Change from Baseline to 2 monthsDescription: Self-reported commitment to healthful diet and physical activity goals. Goal commitment - Healthful eating via the Hollenbeck, Williams, and Klein Goal Commitment Scale. Range: 1-5; higher values represent a better outcome.
Measure: Goal commitment: Healthful eating via the Hollenbeck, Williams, and Klein Goal Commitment Scale Time: Change from Baseline to 2 monthsDescription: Self-reported confidence in performing healthful diet and physical activity behaviors. Self-efficacy - Physical activity via the Self-efficacy for Exercise Behaviors Scale. Range: 1-5; higher values represent a better outcome.
Measure: Self-efficacy: Physical activity via the Self-efficacy for Exercise Behaviors Scale Time: Change from Baseline to 2 monthsDescription: Self-reported commitment to healthful diet and physical activity goals. Goal commitment - Physical activity via the Hollenbeck, Williams, and Klein Goal Commitment Scale. Range: 1-5; higher values represent a better outcome.
Measure: Goal commitment: Physical activity via the Hollenbeck, Williams, and Klein Goal Commitment Scale Time: Change from Baseline to 2 monthsDescription: Self-reported confidence in patient engagement. Health Confidence. Range: 0-12; higher values represent a better outcome.
Measure: Health confidence: the Health Confidence Score Time: Change from Baseline to 2 monthsChronic kidney disease (CKD) is a serious and growing public health problem. The purpose of this study is to find out if an educational worksheet, called the Encounter Decision Intervention (EDI), combined with health coaching helps CKD patients improve their blood pressure and other health outcomes. The research team hypothesizes that the intervention group will have greater improvement in CKD outcomes than the control group.
Description: Changes in systolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.
Measure: Change in Systolic Blood Pressure between baseline and 12 months Time: Baseline, 12 monthsDescription: Changes in diastolic blood pressure between baseline and 12 months will be compared between the intervention group and control group.
Measure: Change in Diastolic Blood Pressure between baseline and 12 months Time: Baseline, 12 monthsDescription: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.
Measure: Slope of systolic BP between baseline and 12 months using all available BP values Time: Baseline up to 12 monthsDescription: BP will be collected at 4 time points - baseline, 1, 6, 12 months. This will be compared between the intervention group and control group.
Measure: Slope of diastolic BP between baseline and 12 months using all available BP values Time: Baseline up to 12 monthsDescription: This is a 28-item questionnaire measuring objective CKD disease knowledge and includes questions about goals, cardiovascular risk, and anti-hypertensive medications. Patients will answer the questions with a yes or no answer and their score will be based on how many responses were correct. This number will be converted to a percentage.
Measure: CKD knowledge measured by the Kidney Knowledge Survey (KiKS) Time: Baseline up to 12 monthsDescription: This is a 13-item measure with the answers on a Likert scale of 1 (not at all sure) to 4 (extremely sure). The higher the score the higher the self-efficacy, with a range from 13-52.
Measure: Medication Adherence Self-Efficacy Scale-Revised (MASES-R) Time: Baseline up to 12 monthsDescription: This scale is to quantify adherence to pharmacological treatments by means of 8 items. Patients will answer yes or no to these items, where a no response = 1 point and a yes response = 0 points. Levels of adherence are based on the following scores: 3-8 = low adherence; 1-2 = medium adherence; 0 = high adherence.
Measure: Morisky Medication Adherence Scale (MMAS - 8) Time: Baseline up to 12 monthsDescription: Length of time provider spends with the patient. This will be compared between the intervention group and control group.
Measure: Visit Time with provider Time: Enrollment visit (baseline)Description: Length of time between patient check-in and check-out. This will be compared between the intervention group and control group.
Measure: Total time in clinic Time: Enrollment visit (baseline)Description: This contains a 17-item questionnaire in which the participants select scores from 1-7 or does not apply. A number of 1 = not at all and a score of 7 = considered very true, and zero = not applicable.
Measure: Patient Motivation by the Treatment Self-Regulation Questionnaire scale (TSRQ) Time: Baseline up to 12 monthsDescription: This is a 15-item questionnaire that assesses the quality of physician to patient communication completed by the patients. There are 5 answers to choose from; poor, fair, good, very good, and excellent. The Score range is 1-5, where 1 means negative perception of communication and 5 means positive perception of communication.
Measure: Satisfaction with CKD care based on Communication Assessment Tool (CAT) Time: Baseline up to 12 monthsDescription: This is a 21-item questionnaire that is completed by the patients, and select from the the 4 choices: very strongly agree, strongly agree, agree, and neutral/disagree. Each answer is worth one point on a Likert scale with a higher score meaning more satisfied.
Measure: Satisfaction with CKD care based on Consultation Care Measure (CCM) Time: Baseline up to 12 monthsDescription: During health coach phone calls, participants will be asked 37 questions about their perceptions of the health coach program, including how much their participation in CHECK-D helped participants change various behaviors. Participant responses will be used to examine various measures of reliability and validity during the analyses of data acquired though this survey.
Measure: Perceptions of health coaching for the intervention group Time: Baseline up to 12 monthsDescription: The EMR will be reviewed to evaluate the patients medication refills for adherence.
Measure: Medication adherence from the electronic medical record (EMR) Time: Baseline up to 12 monthsDescription: This is an 8-item scale regarding self-efficacy where each statement is rated on the level of agreement from 1-5. 1 is disagree and 5 is agree.
Measure: Self-efficacy for disease self-management based on The Perceived Kidney/Dialysis Self-Management Scale (PKDSMS) Time: Baseline up to 12 monthsDescription: This is a 5-item survey about knowledge and behaviors regarding sodium in the diet.
Measure: Self-reported Blood Pressure-Related Behaviors Survey Time: Baseline up to 12 monthsDescription: Provider adoption will be measured by the percentage of enrolled patients whose providers used the EDI with them during their visit. Data will be collected by EMR query and a 1-item question in the patient survey.
Measure: Provider Adoption based on EMR query and patient survey Time: BaselineDescription: Provider fidelity will be measured by the percentage of enrolled patients in the intervention clinics whose providers entered 1-2 patient specific goals in the EDI. This will be collected through EMR query.
Measure: Provider Fidelity measured by EMR query Time: BaselineDescription: Provider perception of usefulness will be measured by a survey of 2-3 questions about how useful they thought it was.
Measure: Provider Perception of Usefulness by provider survey Time: Baseline up to 12 monthsDescription: Change in Serum Creatinine between baseline and 12-months
Measure: Change in serum creatinine Time: Baseline, 12 monthsThe objective of this protocol is to test the effectiveness of a Jumpstart intervention on patient-centered outcomes for patients with chronic illness by ensuring that they receive care that is concordant with their goals over time, and across settings and providers. This study will examine the effect of the EHR-based intervention to improve quality of palliative care for patients over the age of 65 with chronic, life-limiting illness with a particular emphasis on Alzheimer's disease and related dementias (ADRD). The specific aims are: 1) to evaluate the effectiveness of a novel EHR-based (electronic health record) clinician Jumpstart guide, compared with usual care, for improving the quality of care; the primary outcome is documentation of a goals-of-care discussion during the hospitalization. Secondary outcomes focus on intensity of care: ICU use, ICU and hospital length of stay, costs of care during the hospitalization, and 30-day hospital readmissions; and 2) to conduct a mixed-methods evaluation of the implementation of the Jumpstart intervention, guided by the RE-AIM and CFIR frameworks for implementation science, incorporating quantitative assessments of effectiveness, implementation and maintenance and qualitative assessments of clinician perspectives on barriers and facilitators to future implementation and dissemination.
Description: The primary outcome is the proportion of patients who have a goals-of-care (GOC) discussion that has been documented in the EHR in the period between randomization and 30 days following randomization The proportion is the number of patients with GOC documentation over the number of patients in each study arm. Documentation of goals-of-care discussions will be evaluated using our NLP/ML methods. Study staff will manually review and compare findings using a randomly-selected sample of charts using our standard EHR abstraction methods; manual chart abstraction will be the gold standard.
Measure: EHR documentation of Goals of Care discussions Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU admissions during the patient's (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/ICU use: ICU admissions Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the ICU during their (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/ICU use: ICU length of stay Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of days the patient spent in the hospital during that (index) hospital stay will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care/Hospital use: Hospital length of stay Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of hospital readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care: Hospital Readmissions 30 days Time: Assessed for the period between randomization and 30 days following randomizationDescription: Secondary outcomes include measures of intensity of care, including utilization metrics: Number of ICU readmissions between randomization and 30 days following randomization will be collected from the EHR using our automated and validated methods.
Measure: Intensity of care: ICU Readmissions 30 days Time: Assessed for the period between randomization and 30 days following randomizationDescription: Costs for intervention vs. control will be reported in US dollars and identified from UW Medicine administrative financial databases. Costs will be reported for total hospital costs and disaggregated costs (direct-variable, direct fixed, indirect costs). Direct-variable costs will include supply and drug costs. Direct-fixed costs will include labor, clinical department administration, and overhead fees. Indirect costs represent services provided by cost centers not directly linked to patient care such as information technology and environmental services. Costs for ED (emergency department) days and ICU days will be similarly assessed.
Measure: Intensity of care: Healthcare costs Time: 1 and 3 months after randomizationDescription: From Washington State death certificates.
Measure: All-cause mortality at 1 year (safety outcome) Time: 1 year after randomizationDescription: Qualitative interviews after individual participation. Interviews will be guided by the RE-AIM and Consolidated Framework for Implementation Research (CFIR) to explore the factors associated with implementation (e.g., reach, maintenance, feasibility, inner and outer settings, individuals, and processes of care.) Individual constructs within these domains were chosen to fit this specific intervention and context.
Measure: Key Implementation Factors Time: 3 months after randomizationA dynamic analytical tool is being implemented to monitor the health, psychosocial and economic impacts of the COVID-19 pandemic as the crisis unfolds. A longitudinal survey is distributed via a network of hospitals, provincial/national organizations and web platforms. The survey information can be linked to provincial health administrative data and metrics derived from social media activity based on artificial intelligence methods. Targeted questions are included for critical populations such as healthcare workers and people with chronic illnesses.
Description: Cohen's Perceived Stress Scale (scores ranged from 0 to 40, higher scores indicating worse stress)
Measure: Mental health - Stress Time: through study completion, estimated to 8 monthsDescription: Generalized Anxiety Disorder Scale (scores ranged from 0 to 21, higher scores indicating worse anxiety)
Measure: Mental health - Anxiety Time: through study completion, estimated to 8 monthsDescription: Quick Inventory of Depressive Symptomatology-Self-report, short version (scores ranged from 0 to 27, higher scores indicating worse depression)
Measure: Mental health - Depression Time: through study completion, estimated to 8 monthsDescription: Measure of Moral Distress - Healthcare Professionals (scores ranged from 0 to 432, higher scores indicating worse moral distress)
Measure: Moral distress in healthcare workers Time: through study completion, estimated to 8 monthsDescription: Rushton Moral Resilience Scale (scores ranged from 1 to 4, higher scores indicating more resiliency)
Measure: Moral resilience in healthcare workers Time: through study completion, estimated to 8 monthsDescription: Frequency of interacting with other people (daily, weekly, monthly, less often than monthly)
Measure: Social life Time: through study completion, estimated to 8 monthsDescription: Fever, Cough, Difficulty breathing or shortness of breath, Tiredness, Aches and pains, Nasal congestion, Runny nose, Sore throat, Diarrhea (Mild Moderate, Severe, N/A)
Measure: COVID-9 symptoms Time: through study completion, estimated to 8 monthsDescription: Mortality (Yes/No): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Adverse health long-term outcome Time: 5 years before the outbreak and two years afterDescription: Hospitalizations (total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Health care utilization - Inpatient Time: 5 years before the outbreak and two years afterDescription: Emergency Department visits (Total number): https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Health care utilization - ER Time: 5 years before the outbreak and two years afterDescription: Outpatient visits: https://datadictionary.ices.on.ca/Applications/DataDictionary/Default.aspx
Measure: Health care utilization - Outpatient Time: 5 years before the outbreak and two years afterDescription: Pittsburgh Sleep Quality Index (scores ranged from 0 to 21, higher scores indicating worse sleep disturbances)
Measure: Sleep Time: through study completion, estimated to 8 monthsThe containment associated with the VIDOC-19 pandemic creates an unprecedented societal situation of physical and social isolation. Our hypothesis is that in patients with chronic diseases, confinement leads to changes in health behaviours, adherence to pharmacological treatment, lifestyle rules and increased psychosocial stress with an increased risk of deterioration in their health status in the short, medium and long term. Some messages about the additional risk/danger associated with taking certain drugs in the event of COVID disease have been widely disseminated in the media since March 17, 2020, the date on which containment began in France. This is the case, for example, for corticosteroids, non-steroidal anti-inflammatory drugs but also for converting enzyme inhibitors (ACE inhibitors) and angiotensin II receptor antagonists (ARBs2). These four major classes of drugs are widely prescribed in patients with chronic diseases, diseases specifically selected in our study (corticosteroids: haematological malignancies, multiple sclerosis, Horton's disease; ACE inhibitors/ARAs2: heart failure, chronic coronary artery disease). Aspirin used at low doses as an anti-platelet agent in coronary patients as a secondary prophylaxis after a myocardial infarction can be stopped by some patients who consider aspirin to be a non-steroidal anti-inflammatory drug. Discontinuation of this antiplatelet agent, which must be taken for life after an infarction, exposes the patient to a major risk of a new cardiovascular event. The current difficulty of access to care due to travel restrictions (a theoretical limit in the context of French confinement but a priori very real), the impossibility of consulting overloaded doctors, or the cancellation of medical appointments, medical and surgical procedures due to the reorganization of our hospital and private health system to better manage COVID-19 patients also increases the risk of worsening the health status of chronic patients who by definition require regular medical monitoring. Eight Burgundian cohorts of patients with chronic diseases (chronic coronary artery disease, heart failure, multiple sclerosis, Horton's disease, AMD, haemopathic malignancy, chronic respiratory failure (idiopathic fibrosis, PAH) haemophilia cohort) will study the health impact of the containment related to the COVID-19 pandemic.
Description: increase in dose, decrease in dose, discontinuation or no change for each drug class)
Measure: % adherence to each pharmacological class Time: during the period from 20 April 2020 to 7 May 2020Description: (mortality, hospitalizations and relevant criteria for each pathology all related to the chronic disease)
Measure: number of occurrence of medical events at 1 year Time: throughout the study for 12 monthsDescription: Smoking/Smoking/sweetening, Alcohol consumption/recovery, Decreased physical activity, Weight change
Measure: Expressed in %: Non-pharmacological treatment/lifestyle: Time: during the period from 20 April 2020 to 7 May 2020Chronic illness (CI) presents a significant and negative effect on quality of life and mental health. Further, emotion regulation has been considered of particular importance on the determination of chronic patients' well-being. Evidence suggests that Acceptance and Commitment Therapy (ACT) is an effective approach to improve psychological health in patients with CI. Further, there is some, although limited, evidence, that self-compassion training may be also useful in this context, and the inclusion of self-compassion elements in ACT interventions has even been the focus of attention by recent studies. Nevertheless, no study yet has compared the efficacy of these two types of intervention in CI. This is the aim of the present project - to analyse, in a low intensity eHealth intervention context, whether ACT or Compassion Focused Therapy (CFT) present superiority over the other in improving mental health and illness-related outcomes in CI.
Description: Higher scores indicate more depression and anxiety symptoms
Measure: Depression and anxiety (Hospital Anxiety and Depression Scales; HADS) Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessmentsDescription: Higher scores indicate higher levels of illness shame
Measure: Illness shame (Chronic Illness Shame Scale; CISS) Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessmentsDescription: Higher scores indicate higher levels of psychological flexibility
Measure: Psychological Flexibility (Comprehensive assessment of ACT processes; CompACT) Time: Pre-intervention, post-intervention, and 3 and 6-month follow-upsDescription: Higher scores indicate higher levels of self-compassion (subscale of the Self-compassion scale)
Measure: Self-compassion (Self-compassion scale; SCS) Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessmentsDescription: Higher scores indicate higher levels of self-cristicism (subscale of the Self-compassion scale)
Measure: Self-criticism (Self-compassion scale; SCS) Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessmentsDescription: Higher scores indicate higher levels of cognitive fusion
Measure: Cognitive fusion (Cognitive Fusion Scale; CFQ-7) Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessmentsDescription: Higher scores indicate more fear of contracting COVID-19
Measure: Fear of contracting COVID-19 (Fear of contracting COVID-19 scale; FCCS) Time: Changes in results from: immediately pre-intervention and immediately post-intervention assessmentsIn Barbados, levels of hypertension are high (40.7%) and cause of a high proportion of deaths due to cardiovascular diseases. In this study, the Stanford University-led Chronic Disease Self-Management Program (CDSMP) will be modified to form one of the basic components of a three-pronged intervention to improve blood pressure control. Our overall goal is to evaluate the effectiveness of a hypertension self-management program in community-based settings. With the advent of the Coronavirus disease 2019 (COVID-19) we recognize that it may be necessary to adapt the programme to accommodate virtual delivery. Our specific aims are to: 1. Adapt the Stanford (CDSMP) to ensure cultural appropriateness to Barbados. In view of the need to adhere to physical distance guidelines in the era of COVID-19 disease, modifications will be made to enhance virtual delivery while maintaining programme fidelity. We will engage stakeholders in performing modifications related to content, context and mode of delivery of the CDSMP program with the goal of ensuring cultural appropriateness. 2. Determine the clinical effectiveness of CDSMP combined with medication enhancement tools. We will conduct a cluster randomized trial in twelve faith-based organizations(FBOs) in Barbados. We are primarily interested in studying the changes in systolic blood pressure. Secondarily, we will also assess change in weight, medication adherence, dietary behavior and physical activity. 3. Understand the barriers and facilitators to implementation and sustainability of CDSMP plus self-monitoring tools in faith-based organizations. We will assess cost and sustainability of the intervention and qualitatively assess factors associated with barriers and facilitators of implementation in FBOs in Barbados. Impact and novelty: We aim to increase the proportion of patients with controlled hypertension leading to reduced illness and deaths from strokes and heart attacks in particular. Few studies have looked at a blended approach to CDSMP delivery and these will become more necessary in the era of COVID-19. Findings on the factors impacting implementation will be transferable to small island developing states and other predominantly black populations.
Description: We will measure systolic blood pressure before and 6 months after the interventions
Measure: Systolic blood pressure Time: Six monthsDescription: We will measure participants' weight in kilograms before and six months after the intervention
Measure: Mean weight change for intervention and control groups Time: Six monthsDescription: Changes in dietary behavior will be monitored by using the Dietary Approaches to Stop Hypertension Accordance Score. Score ranges from 0 to 9. A low score represents a poor diet for hypertension control. The higher the score the more appropriate for hypertension control.
Measure: Level of adherence to the Dietary Approaches to Stop Hypertension (DASH) Diet Time: Six monthsDescription: Using the results of the GPAQ median physical activity in MET-minutes per week will be calculated before the intervention as well as six months post intervention
Measure: Assessing physical activity levels using the Global Physical Activity Questionnaire (GPAQ) Time: Six monthsDescription: Perceived self-efficacy scores will be calculated using a tool developed by K Lorig(Stanford University School of Medicine) for measuring self-efficacy in chronic disease management programs. Score ranges from 1 to 10. A higher score is better.
Measure: Self-Efficacy for Managing Chronic Diseases 6-item Scale Time: Six monthsAs of May 30th more than 23,000 cases of COVID -19 cases were confirmed in Egypt with total deaths of 913. Post viral entry, intense immune response against the virus with infiltration of monocytes and macrophages into alveolar cells with decreasing number of lymphocytes in peripheral blood along with reduced lymphocytes in lymphoid organs, hypercoagulability, thrombosis and multiple organ damage, The gut microbiota and immune homeostasis seem to have a back and forth relationship. Also, gut microbiota derived signals are known to tune the immune cells for pro and anti-inflammatory responses thereby affecting the susceptibility to various diseases. Healthy gut microbiome essentially could be pivotal in maintaining an optimal immune system to prevent an array of excessive immune reactions that eventually become detrimental to lungs and vital organ systems. Numerous studies have shown that the patient's nutritional status have a significant effect on an individual's immunity and over all health status and it has been suggested that nutritional deficiencies may predispose to severe forms of COVID-19 infections. Co-existing non-communicable chronic diseases (NCDs) in COVID-19 patients have been found to delay patients recovery and worsen their prognosis, the reason may be due to aggravated inflammatory pathology found in NCDs exacerbating COVID-19 infection. The aim of the study is to evaluate the role dietary habits among COVID-19 Egyptian patients and whether type of diet (Mediterranean or Western) will affect disease outcomes
Description: To assess the relation between type of diet in mild to moderate COVID 19, to the fate of their course; either improvement or progression
Measure: Western versus Mediterranean diet in COVID-19 outcome Time: 2 monthsDescription: To asses any possible links between gut microbiome and the lung affecting clinical presentation of mild to moderate COVID cases; as diarrhea, loss of taste or smell
Measure: Gut- Lung axis in COVID-19 Time: 2 monthsDescription: Possible protective effects of minerals and vitamins against COVID-19 respiratory illness
Measure: Protective role of minerals and vitamins in COVID-19 patients Time: 2 monthsDescription: Trying to explain the link between non-communicable disease severity and COVID-19 prognosis
Measure: non-communicable diseases and COVID-19 Time: 2 monthsData show that the coronavirus disease 2019 (COVID-19) symptoms can be severe in 4% and 3% of the adolescents aged 11-15 years and ≥ 16 years, respectively. In addition, the prevalence of chronic diseases among adolescents has increased in the last years. About 20% of the adolescents have some chronic disease, resulting in increased morbidity and mortality. In march, 2020, the quarantine was officially implemented in Sao Paulo, while elective medical appointments for adolescents with chronic disease were temporarily suspended. To mitigate the deleterious effect of the social isolation on physical and mental health among these patients, this study aims to test the effects of an online, home-based, exercise training program.
Description: Semi structured interview
Measure: Safety and efficacy of a home-based exercise training program Time: From baseline to 3 months of follow-upDescription: Semi structured interview
Measure: Patients perceptions during social isolation Time: From baseline to 3 months of follow-upDescription: Quality of life will be assessed by means of Pediatric Quality of Life inventory (PedsQLTM 4.0)
Measure: Adolescents quality of life Time: From baseline to 3 months of follow-upDescription: Will be assessed by means of a visual analog scale (from 0 - no disease activity) to 10 - maximum disease activity).
Measure: Disease activity Time: From baseline to 3 months of follow-upDescription: Will be assessed using the visual analog scale from 0 (very good condition) to 10 (very poor condition).
Measure: Disease overall assessment Time: From baseline to 3 months of follow-upDescription: Will be assessed by means of Strengths & Difficulties Questionnaires
Measure: Strengths and difficulties Time: From baseline to 3 months of follow-upThe principal objective of the study is to determine if patient-empowered, real-time and home- based patient monitoring of vital parameters can lead to: - Reduction in admission rates and improved clinical management of chronically ill patients - Reduction in use of medications - Reported quality of life A minimum of 100 patients will be recruited, monitored and observed over 6 months from home with the Coala Heart Monitor. The study population will be representative of rural, high-risk, Medicare (65+ of age) subjects with chronic conditions and will be recruited by the Perry Community Hospital in Linden, TN.
Description: As measured by Rand-36
Measure: Increased quality of life Time: 6 monthsDescription: The cloud-based Coala Care platform enables patient data to be shared and accessed efficiently with affiliated specialists. Show how this helps improve clinical management and healthcare processes.
Measure: Show the value of using Coala Heart Monitor in rural care - providers Time: 6 monthsThe purpose of this study is to ensure effective health management among community-living older adults during unprecedented times, such as the current COVID-19 pandemic.
Description: Health Education Impact Questionnaire (HeiQ) that evaluates health directed behaviour for chronic disease management.
Measure: Change from baseline: Health Directed Behaviour at 2 months Time: Baseline, Post-intervention (immediately after the 2-month intervention)Description: 21-item survey scale that looks at perceived depression, anxiety and stress.
Measure: Depression, Anxiety, Stress Scale Time: Baseline, Post-intervention (immediately after the 2-month intervention)Description: 19-item survey that evaluates perceived social support.
Measure: Medical Outcomes Study (MOS): Social Support Survey Time: Baseline, Post-intervention (immediately after the 2-month session)Description: Survey scale that evaluates at health-related quality of life.
Measure: Medical Outcomes Study (MOS): Short Form-36 Time: Baseline, Post-intervention (immediately after the 2-month session)Description: 28-item survey scale that looks at health promotion self-efficacy.
Measure: Self-Rated Abilities for Health Practices Scale Time: Baseline, Post-intervention (immediately after the 2-month session)Description: Health Education Impact Questionnaire
Measure: Self-management Time: Baseline, Post-intervention (immediately after the 2-month session)The sustainability of the United Kingdom's National Health Service's (NHS) is threatened immediately by Covid-19 and continually by an increasing prevalence of long-conditions that cannot be cured but can be maintained. Shifting traditional face-to-face outpatient appointments to remote video consultations may help the NHS continue to serve patients efficiently. While much research has examined healthcare providers' attitudes and beliefs about remote video consultations, less has attempted to understand how NHS service providers should invite patients to attend them. The present study examines how the framing of an invitation to attend a hospital outpatient appointment by video influences the proportion of people who agree to attend by video. It also explores some of the barriers and facilitators people may experience to attending appointments by video across diagnostic complexities and age groups. The results of this study should help hospitals better present patients with the option to attend video consultations where appropriate, and provide support to mitigate common barriers to people's willingness to give video consultations a go.
Description: Participants responses will indicate whether they would prefer a video or in-person appointment.
Measure: Response to the outpatient invitation Time: One dayAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports